Your browser doesn't support javascript.
loading
PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.
Packer, Leisl M; Geng, Xinyan; Bonazzi, Vanessa F; Ju, Robert J; Mahon, Clare E; Cummings, Margaret C; Stephenson, Sally-Anne; Pollock, Pamela M.
Afiliação
  • Packer LM; Endometrial Cancer Laboratory, Queensland University of Technology (QUT), Translational Research Institute, Queensland, Australia.
  • Geng X; Endometrial Cancer Laboratory, Queensland University of Technology (QUT), Translational Research Institute, Queensland, Australia.
  • Bonazzi VF; Endometrial Cancer Laboratory, Queensland University of Technology (QUT), Translational Research Institute, Queensland, Australia.
  • Ju RJ; Endometrial Cancer Laboratory, Queensland University of Technology (QUT), Translational Research Institute, Queensland, Australia.
  • Mahon CE; Endometrial Cancer Laboratory, Queensland University of Technology (QUT), Translational Research Institute, Queensland, Australia.
  • Cummings MC; School of Medicine, University of Queensland Centre for Clinical Research, Queensland, Australia.
  • Stephenson SA; Eph Receptor Biology Group, Queensland University of Technology (QUT), Translational Research Institute, Queensland, Australia.
  • Pollock PM; Endometrial Cancer Laboratory, Queensland University of Technology (QUT), Translational Research Institute, Queensland, Australia. pamela.pollock@qut.edu.au.
Mol Cancer Ther ; 16(4): 637-648, 2017 04.
Article em En | MEDLINE | ID: mdl-28119489
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Pirimidinas / Sulfonamidas / Tiazóis / Protocolos de Quimioterapia Combinada Antineoplásica / Morfolinas / Neoplasias do Endométrio / Receptor Tipo 2 de Fator de Crescimento de Fibroblastos / Aminopiridinas / Indazóis Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Austrália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Pirimidinas / Sulfonamidas / Tiazóis / Protocolos de Quimioterapia Combinada Antineoplásica / Morfolinas / Neoplasias do Endométrio / Receptor Tipo 2 de Fator de Crescimento de Fibroblastos / Aminopiridinas / Indazóis Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Austrália